MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$33,301K
Free Cash flow
-$18,799K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of common...
    • Proceeds from exercises of stock...
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Prepaid expenses and other curre...
    • Lease liabilities, net
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-24,657
-18,581
-17,433
-55,348
Depreciation
88
88
93
90
Amortization of intangible assets
166
167
166
166
Stock-based compensation
4,973
1,912
4,970
5,617
Non-cash lease expense
317
308
306
847
Write-off of deferred issuance costs
0
281
-
-
Loss on disposal of fixed assets
-
-
0
-
Other
-12
-62
-
-
Accounts receivable
-43
-55
259
15
Inventory
30
70
79
57
Prepaid expenses and other current assets
433
129
374
538
Other receivables
-
-
-
14
Other non-current assets
-4
-3
-14
28
Accounts payable
139
-148
-186
1,318
Accrued liabilities
1,052
1,832
-1,627
-1,823
Lease liabilities, net
-383
-375
-360
-1,008
Net cash used in operating activities
-18,709
-14,595
-14,755
-13,039
Purchases of property and equipment
90
33
105
62
Purchases of intangible assets
0
-
0
0
Net cash used in investing activities
-90
-33
-105
-62
Proceeds from issuance of common stock under at-the-market offering program, net of issuance costs
46,392
-
-
-
Proceeds from exercises of stock options
5,612
1,674
387
1,708
Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs
-
-
0
0
Proceeds from exercises of warrants, net of issuance costs
39
130
1
17
Payment of deferred issuance costs in relation to registration statements
-
57
0
0
Proceeds from issuance of common stock under employee stock purchase plan
0
465
-7
241
Net cash provided by financing activities
52,100
2,212
381
1,966
Net increase (decrease) in cash and cash equivalents
33,301
-12,416
-14,479
-11,135
Cash and cash equivalents at beginning of period
95,214
95,214
-
118,038
Cash and cash equivalents at end of period
101,620
68,319
-
95,214
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofcommon stock under...$46,392K Proceeds from exercisesof stock options$5,612K (1331.63%↑ Y/Y)Proceeds from exercisesof warrants, net of...$39K (-99.72%↓ Y/Y)Net cash provided byfinancing activities$52,100K (251.86%↑ Y/Y)Net increase(decrease) in cash and cash...$33,301K (384.89%↑ Y/Y)Canceled cashflow$18,799K Stock-based compensation$4,973K (-54.25%↓ Y/Y)Accrued liabilities$1,052K Non-cash lease expense$317K Amortization of intangibleassets$166K (-50.15%↓ Y/Y)Accounts payable$139K Depreciation$88K (-60.54%↓ Y/Y)Accounts receivable-$43K Other-$12K Other non-currentassets-$4K Net cash used inoperating activities-$18,709K (28.94%↑ Y/Y)Net cash used ininvesting activities-$90K (46.43%↑ Y/Y)Canceled cashflow$6,794K Net loss-$24,657K Purchases of property andequipment$90K (-39.19%↓ Y/Y)Prepaid expenses andother current assets$433K Lease liabilities,net-$383K Inventory$30K

PULSE BIOSCIENCES, INC. (PLSE)

PULSE BIOSCIENCES, INC. (PLSE)